Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics' stock has experienced significant fluctuations over the past six months. The stock price has fallen by -17.47% over the last six months and by -30.78% in the last 10 days leading up to February 6, 2026. On February 6, 2026, the stock gained 2.56%, rising from $0.81 to $0.83, though it fluctuated 6.74% during that day. Key events include Stenoparib receiving FDA Fast Track designation in August 2025 and Phase 2 trial data showing a median overall survival exceeding 25 months in September 2025. Allarity provided its Third Quarter 2025 Financial Results and Business Updates on November 14, 2025, and issued its 2025 End of Year CEO Letter to Shareholders on December 31, 2025. On February 3, 2026, Allarity announced that its collaborative Phase 2 trial with the U.S. Veteran's Administration was open for enrollment. Insider sentiment for ALLR is positive, with insiders buying $2.21 million worth of shares. Analyst ratings vary, with one analyst issuing a "Strong Buy" rating and another source indicating a consensus rating of "Hold".

Information regarding demand seasonality for Allarity Therapeutics' products and services is not readily available. As a clinical-stage pharmaceutical company, its primary focus is on drug development and clinical trials rather than commercial product sales, which typically exhibit seasonality.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapeutics. It operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company uses its Drug Response Predictor (DRP®) technology to personalize cancer treatment. Its lead product candidate is Stenoparib, being evaluated in a Phase 2 clinical trial for advanced and recurrent ovarian cancer. Allarity also develops Stenoparib-DRP, a companion diagnostic product. In 2024, Allarity focused on Stenoparib, discontinuing other clinical programs.

Allarity Therapeutics operates in Denmark and the United States. The company's headquarters are located in Boston, Massachusetts, U.S.A., and it maintains an R&D facility in Hoersholm, Denmark.

Allarity Therapeutics' brand reputation has been influenced by positive clinical developments and financial challenges. The FDA Fast Track designation and promising Phase 2 clinical trial results enhance the company's scientific and clinical reputation. Financial challenges, including net losses and liquidity issues, contribute to a negative outlook. Analyst sentiment is mixed, with an overall consensus rating of "Hold".

Allarity Therapeutics has a relatively low institutional float, with 13 institutional owners holding 1,159,706 shares. Major institutional owners include Private Advisor Group, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. The majority of the common stock (approximately 97.16%) is held by insiders, founders, and retail investors.